Skip to main content

Marcos Lacasa Cazcarra

Institutions of which they are part

Postdoctoral researcher
Rheumatology
Vall Hebron Institut de Recerca

Marcos Lacasa Cazcarra

Institutions of which they are part

Postdoctoral researcher
Rheumatology
Vall Hebron Institut de Recerca

Related news

The new therapeutic strategy aims at maintaining the efficacy of thalidomide while avoiding its main systemic adverse effects.

The event, held as part of World Lupus Day, incorporated the perspective of people living with the disease to address the challenges associated with lupus.

The global biopharmaceutical company UCB has acquired the data and clinical knowledge business of IMIDomics, a spin-off of the Vall d’Hebron Institute of Research (VHIR).

Related professionals

Habby Jawo Baldeh

Habby Jawo Baldeh

Maintenance staff and general services
Infectious Diseases
Read more
Imane EL Haddioui Assarraj

Imane EL Haddioui Assarraj

Maintenance staff and general services
Infectious Diseases
Read more
Maria Eugenia Palacio Lacambra

Maria Eugenia Palacio Lacambra

Postdoctoral researcher
Basic, Translational and Clinical Pharmacy Research
Read more
Mariona Morell Daniel

Mariona Morell Daniel

Predoctoral researcher
Childhood Cancer and Blood Disorders
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.